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Abstract
Dendritic cellls (DCs) comprise an essential component of the immune system. These cells, as
antigen presenting cells (APCs) to naïve T cells, are crucial in the initiation of  antigen specific
immune responses. In the past years, several DC subsets have been identified in different organs
which exert different effects in order to elicit adaptive immune responses. Thus, identification of
such DC subsets has led to a better understanding of their distribution and function in the body.
In this review, several key properties of the immunobiology, immunopathogenesis and vaccine
strategies using DCs will be discussed.
Review
Dendritic cellls (DCs) are a complex, heterogeneous
group of multifunctional APCs. DCs are leukocytes, dis-
tributed throughout lymphoid and non-lymphoid tissues,
in peripheral blood and afferent lymph vessels [1]. It has
been shown that DCs after activation with different stim-
uli achieve maturation, where they express high levels of
several molecules on the cell surface such as MHC class I
and II, accessory molecules CD40, CD80, CD86 and early
activation markers such as CD83. These cells do not pro-
liferate and after a certain time course they undergo apop-
tosis and will be replaced by a new pool of cells [1].
Functionally, DCs exert various effects on other immune
cells, particularly in secondary lymphoid organs; DCs
present non-self peptide-MHC complexes to naïve and
memory T lymphocytes to mobilize specific immunity [1-
4]. By contrast, in order to induce T cell-tolerance in the
thymus, DCs present self peptide-MHC complexes to thy-
mocytes [5]. The capacity of DCs to initiate primary
immune responses is due to their ability to deliver specific
costimulatory signals which are essential for T cell activa-
tion from the resting or naive state into distinct classes of
effector cells. These immunogen-specific immune
responses are critical for example, to tumor resistance,
prevention of metastasis, and blocking infections. DCs
also can alter the function of regulatory T cells that control
activated T cells through their suppressive signals. In addi-
tion, DCs play an important role in innate immunity by
secreting cytokines, e.g. IL-12 and Interferon classes I and
II, involved in host defense. Moreover, DCs activate Natu-
ral killer cells (NK) and NKT cells that rapidly eradicate
select targets [1]. Such diverse functions of DCs has begun
to shed light on their pre-eminent role in immunological
events. In this review we highlight several critical aspects
of DCs in order to better understand host-pathogen
interactions.
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Origin and developmental processes of dendritic 
cells
DCs originate from hematopoietic stem cells in the bone
marrow. Recently, there have been great insights into the
origins of DC subsets [6,7] and their modulation by dis-
tinct cytokines of neighboring cells [8,9]. Progenitors of
DCs in bone marrow migrate via the blood stream and
home to peripheral tissues where they encounter several
essential growth factors such as GM-CSF, IL-4, IL-15, TNF-
α, TGF-β, and IL-3 secreted by various cell types including
endothelial cells, Mast cells, keratinocytes and fibroblasts
in the microenvironment (Figure 1). Such growth factors
determine the fate of the progenitors to differentiate into
immature Langerhans DCs, interstitial DCs or plasmacy-
toid DCs (Figure 1).
One of the hallmarks of DC progenitors is their capacity
to migrate [10]. Cutaneous and nonlymphoid DC popu-
lations migrate to T-cell areas (Figure 2). For example,
cutaneous interstitial DCs enter mesenteric lymph nodes
[11]. Liver OX62+ DCs, which reside in the portal triads
[12] and along the sinusoids [13], migrate into hepatic
lymph and subsequently to the celiac lymph nodes [14].
Experimentally it has been shown that isolated DCs from
several organs that were reinfused into animals, within 24
hrs, home to the T cell rich area of the draining lymph
nodes. Homed DCs sample and select very rare antigen
specific primary T cells from the recirculating stream [15].
In addition, DC subsets are ready to confront invading
pathogens [1]. In such environments DCs ingest antigens
via several mechanisms including phagocytosis [15] and
receptor-mediated endocytosis [16]. For example Langer-
hans DCs phagocytose, process, and present immuno-
genic peptides to T cells [1,16,17].
Antigenic infectious agents including vaccines induce pro-
inflammatory cytokines (e.g., TNF-α). These cytokines
promote Langerhans DC maturation in lymphoid organs
where they home to the T cell rich area [18]. Langerhans
DCs undergo phenotypic and functional changes during
their maturation and migration. These cells, which are
now loaded with antigenic peptides on MHC class II,
down-regulate CD1a, CCR6, and E-cadherin, and lose the
capacity to capture foreign antigens [9,18]. Mature DCs
are an end stage of differentiation, and they can not be
converted into either macrophages or lymphocytes.
DCs in general present marked heterogeneity in pheno-
type and function, which relate to their precise localiza-
tions within different tissues in the body. However, DCs
do not express phenotypic markers of T lymphocytes (e.g.
CD3, CD16, CD19, CD28), B cells (Ig and CD19, CD20),
or NK cells (CD 16, CD56, CD57). In some instances,
DCs express molecules that are also expressed on macro-
phages, and while the phenotypic distinction between
DCs and macrophages is not always clear; studies with
respect to their immunostimulatory functions (e.g., pri-
mary Mixed Lymphocyte Reaction) provide clear evidence
between these two types of antigen presenting cells. In
addition, DCs also express surface molecules which are
specifically expressed on T cell subsets (e.g., CD4), and a
DC subset residing in murine lymphoid organs express
CD8α marker [7].
Functions of dendritic cells
The role of DCs has been repeatedly highlighted in cancer
and infectious diseases [1]. Human CD14+ progenitor
DCs cultured in GM-CSF+IL-4 are equivalent to interstitial
DCs (e.g., dermal DCs) and express CD1a, CD64 and Fac-
tor III a [16]. By contrast, monocytes cultured with M-CSF
convert to a monocyte/macrophage phenotype [18].
These myeloid DCs home within lymphoid follicles,
where they reside as germinal center DCs [19]. In this
area, germinal center DCs establish the contact between T-
and B-cells, which may lead to the stimulation of an active
immune response [20]. DCs present processed antigenic
peptides on MHC class II molecules to CD4+ T cells [21],
which will be activated in conjunction with co-stimula-
tory signals (e.g., CD40, CD86) delivered from DCs in
lymphoid organs. Several receptors and their ligands are
involved in the T cell/DC dialogue, e.g., CD40/CD40L
[22]. For instance, up-regulation of CD40L on T cells facil-
itates DC maturation [23]. Activated DCs then release
cytokines such as IL-12, which modulate and stimulate
the production of IFN-γ from T cells [24]. Activated DCs
can either prime naive CD8+ T cells, or they undergo apop-
tosis in situ [25]. Activated T cells migrate to the area of the
B-cell follicles via activated adhesion molecules [26-28].
There they interact with naïve antigen-specific B cells [29].
T- and B-cell interaction results in the clonal expansion of
B cells, which takes place in the plasma foci of the T cell
rich area [30] and in the germinal centers [31]. T- and B-
cell dialogue in the germinal center might be influenced
by germinal center DCs [20] and follicular DCs [30] (Fig-
ure 3).
Dendritic cells and T-cell tolerance
T cells before they encounter immunogenic antigens must
undergo a step where the T cell repertoire is tolerized to
self-antigen. This process when it occurs in the thymus is
called central tolerance. It occurs by deletion of develop-
ing T lymphocytes; in the lymphoid organs, it is called
peripheral tolerance by probably eliminating or anergiz-
ing committed mature T cells. In both situations, as dis-
cussed before, DCs not only induce primary antigen
specific T cell immune responses but these cells also
appear to induce tolerance of T cells to self-antigens. DCs
present self-antigen via MHC class molecules in the
thymic medulla. Experimentally it has been shown that ifJournal of Immune Based Therapies and Vaccines 2004, 2 http://www.jibtherapies.com/content/2/1/1
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Human DC subsets Figure 1
Human DC subsets. DC progenitors migrate from the bone marrow in the periphery and several different tissues. There 
they encounter various growth factors which determine the fate of these cells to differentiate into immature DC subsets.
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antigen-loaded DCs are administrated to developing or
fetal thymus reactive T lymphocytes, they will be deleted
indicating that DCs play a critical role in this process.
Moreover, in the cortical area of the thymus, although
macrophages phagocytize dying T cells which did not
undergo positive selection these cells seem not to be
involved in deleting auto-reactive T cells. Studies show
that if MHC class II molecules are solely expressed by the
cortical epithelium and not by DCs residing in the
medulla, there is a higher probability towards an autoim-
mune disease. These results highlight the critical role of
DCs in educative processes of thymic T cells to self-anti-
gens. In addition, DCs play a critical role in peripheral tol-
erance by presenting self-antigen to T cells residing in
specialized tissues such as the pancreas [32,33]. Presenta-
tion of processed self-antigen as peptides by DCs ensures
T cell tolerance probably through T cell deletion or anergy
[32-34].
The role of dendritic cells in clinical diseases
Recent studies shed light on the role of DC involvement
in various diseases such as autoimmunity, allergy, trans-
plantation, infection and cancer. For example, studies
showed that DCs differentiated in vitro express very
important co-stimulatory molecules, e.g. CD40, which
allow these cells to approach T cells and deliver signals to
them [22,23]. With respect to that phenomenon,
Migration of immature DCs into lymphatic organs Figure 2
Migration of immature DCs into lymphatic organs. Skin surrounded by various immunogen antigens that can penetrate 
the epidermis. These antigens can be captured by immature Langerhans DCs, and processed. Cutaneous DCs will then be acti-
vated, migrate, and home to the lymph nodes. Matured DCs present processed antigen to antigen specific T cells inducing spe-
cific immunity.
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cytokines (e.g., GM-CSF, TNF-α) produced by keratinoc-
ytes affect DC differentiation dramatically [35]. Moreover,
DCs alone produce essential cytokines (e.g. IL-1β, TNF-α,
IL-6), and chemokines MIP-1α, MIP-1γ, IL-15 and IL-8
[9,36-39]. Some of these cytokines contribute directly to
the DCs ability to attract and recruit T cells in sites of
inflammation. A number of autoimmune diseases (rheu-
matoid arthritis) or skin psoriasis demonstrates the accu-
mulation of DCs in diseased tissues [40]. This evidence
suggests that DC enrichment within the cytokine-rich syn-
osium or epidermis undergo phenotypic and functional
maturation in vivo. Furthermore, it seems that the ligation
of CD40 with DCs can enhance the antigen presenting
capacity of these cells [22]. It has recently been reported
that rheumatoid arthritis synovial T lymphocytes express
CD40L at a low level. These molecules can be dramatically
upregulated when T cells are activated. In this context,
stimulation of self-reactive T lymphocytes in the syno-
sium will be induced through GM-CSF and TNF-α along
with CD80+ C086+ DCs [41].
Induction of primary immune responses by DCs Figure 3
Induction of primary immune responses by DCs. The DC lineage comprises cells at different stages of differentiation 
and development in different tissues. The currently accepted scheme suggests that DCs from bone marrow move via the blood 
into non-lymphoid tissues. In these organs they undergo different changes with respect to shape, functions. In these organs 
DCs induce primary T cell immune responses.
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As mentioned above, cytokines can control the develop-
ment and differentiation of DCs. For example, the
combination of GM-CSF and TNF-α can promote
differentiation of CD34+ blood stem cells into DCs in
humans [6]. Phenotypically these cells are CD4+CD11C+
since Langerhans DCs and other DC family numbers
express CD4 molecules that can bind to the HIV surface
envelope protein gp 120 [42]. This makes a possibility
stronger that DCs may contribute to HIV pathology. On
one hand, in vivo and in vitro experiments indicate that
the replication of HIV-1 virus occurs during cognate CD4+
T cell activation through DCs. On the other hand, there is
evidence that the features of HIV pathology are an accu-
mulation of HIV virus in the germinal centers, which is T
cell rich and where a novel DC population has recently
been identified [20]. Both the APC function of DCs and
their close interaction with CD4+ T cells suggests that ger-
minal centers of lymph nodes may provide an additional
site for HIV viral replication [42-44].
Moreover, DCs in transplanted organs are involved and
they represent potent "passenger leukocytes" that sensi-
tize host graft antigens and trigger rejection [45]. Studies
have shown that the depletion of DCs from mouse islets
or thyroid tissue prolonged survival in allogeneic recipi-
ents [45]. Other studies on the function of DCs after trans-
plantation of skin and heart tissues to allogeneic
recipients have shown that soon after grafting, DCs enter
the recipient's lymphoid tissues [46]. Thus, there appears
to be a sensitization of host T cells which occurs primarily
in these tissues when they encounter the graft-derived, all-
ogeneic DCs. Austyn et al. showed recently that host DCs
can also present graft antigens to host T cells [46]. In this
process it seems that host DCs bearing graft molecules
would migrate into the secondary lymphoid organs to
sensitize and activate T lymphocytes and induce graft
rejection.
It is clear now, that cancer cells can express tumor associ-
ated antigens, which are recognized by host T cells. These
T cells may not be able to reject tumor cells. These mole-
cules, then, are not immunogenic. In order to become
immunogenic they must be processed and presented by
professional antigen presenting cells (APC). Since DCs
possess relevant features, e.g. a) internalizing of immuno-
genic antigen through endocytosis, b) phagocytosis for
subsequent processing and presentation of several anti-
gens to T cells, and c) migration capability, they could
acquire tumor antigen.
In the past few years the role of DCs in cancer has been
suggested. There is evidence that DCs can induce immu-
nity to tumors if they are administrated to animals or
exposed to tumor associated antigen (TAA) before or
when the tumor is inoculated into animals [47-49]. For
example, Boczkowski et al. [50] conducted several elegant
experiments to demonstrate that DCs pulsed with synthe-
sized chicken ovalbumin (OVA) RNA were more effective
than OVA peptide-pulsed DCs in activating primary OVA
specific-CTL responses in vitro. This finding shows that the
amplification of antigens from a small number of tumor
cells is feasible, thus increasing the possibility of utilizing
RNA-pulsed DC based vaccines for patients bearing very
small tumors [50].
Studies demonstrate that when DCs are pulsed with
tumor antigens in ex vivo, and these cells subsequently
readministrated, specific immunity is established [51]. In
addition, several studies showed that tumor-specific CD8+
cytotoxic T lymphocytes (CTL) constitute an important
effector arm of the anti-tumor immune response [52,53].
In this context to elicit specific immunity against tumor
cells, DCs were pulsed with protein or peptide in the pres-
ence of lipid [54] or transfected with DNA [55] were capa-
ble of eliciting primary CTL responses in vitro.
Although prior investigations have established that target-
ing immune cells to tumors may improve immunity [47-
55], in the case of DCs, however, it has been shown [56-
62] that the tumor microenvironment is detrimental to
DC function, and in fact may condition DCs to induce a T
cell response that anergizes or suppresses tumor-specific
immunity [56]. Thus, targeting DCs directly to tumors, as
demonstrated by several studies, may be inefficient.
Therefore, methods should be developed in order to target
DCs by immunogenic TAAs outside the tumor microenvi-
ronment to improve immunity.
Vaccine design by targeting dendritic cells
Given the central role of DCs in controlling immunity,
has brought a scientific focus to the critical role of DCs as
an efficient vector in vaccine technology. Several
approaches to target DCs efficiently have been designed.
There is a large body of literature involving experimental
animal models and for tumors and infection in which DC
subsets pulsed with TAAs or subunits of the pathogens
such as HCV or HIV are to induce protective immunity
against tumors. However, it is even more important to cre-
ate novel strategies by targeting immunogenic antigens or
immune regulatory agents specifically to DCs without
impairing the functional properties of DC subsets and in
this way modulate the immune responses in vivo.
These novel strategies must not be too costly, not immu-
nopathogenic, but specific in order to overcome anergy
established through negative signals which may be pro-
vided by immune component cells including DCs to the
microenvironment.Journal of Immune Based Therapies and Vaccines 2004, 2 http://www.jibtherapies.com/content/2/1/1
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One possible strategy is to target novel molecules
expressed on the cell surface of DCs. In this, we and others
utilized phage display peptide library to generate small
peptides which solely bind to DC subsets and not other
cells. DNA sequences encoding DC-peptides can then be
fused genetically with TAA coding regions or with the sub-
unit of the pathogen of interest. Immunogenic fusion pro-
teins can be then expressed by probiotic microorganisms
such as Lactobacilli or attenuated strains of Salmonella in
vivo (Figure 4). Such novel vaccine strategies should take
advantage of mucosal sites in the body, as well as the skin
in order to be delivered specifically to DC subsets in vivo
(Figure 5).
The Peyer's patch is the primary mucosal site for antigen
processing in the intestine. Recent in vivo studies provide
evidence that DC network in the subepithelial dome of
Peyer's patches is a critical component in the uptake and
processing of luminal antigens. Such uptake may occur by
endocytosis or by phagocytosis after passage of antigen
through M cells. The DCs then present the processed anti-
gen to CD4+ or CD8+ T cells in the subepithelial dome, or
after maturation and migration, to the interfollicular
regions where antigen is presented to CD4+/CD8+ T cells
[63]. In this regard, immunohistologic analysis of DC
subsets including LCs in Peyer's patch has revealed that
the unique microanatomical localization of DC subsets
Delivery of immunogenic antigen to DCs by probiotic microorganisms Figure 4
Delivery of immunogenic antigen to DCs by probiotic microorganisms. DNA encoding sequences of DC-binding 
peptides and immunogenic subunit of any pathogen will be expressed in Gram positive bacteria including Lactobacillus. Lactoba-
cillus will be orally administrated. These bacteria colonize the gut and express and release the immunogen in the intestine. DCs 
in the mucosal site will then capture the immunogen via DC-binding peptide motifs. They internalize the immunogen, process 
and present it to T cells inducing specific responses against released immunogen.Journal of Immune Based Therapies and Vaccines 2004, 2 http://www.jibtherapies.com/content/2/1/1
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enables them to regulate specific T- and B-cell responses in
vivo [63-65]. Other, studies also clearly demonstrated that
Gram-positive bacteria such as Lactobacilli can successfully
be used in order to deliver vaccine peptides to immune
component cells [66-68].
More specifically, in order to target any vaccine to DCs,
recently, a novel strategy was proposed. Mohamadzadeh
et al. fused a subunit of hepatitis C virus with a DC-bind-
ing peptide. Studies are ongoing to express such immuno-
genic fusion proteins by a strain of Lactobacilli [69]. Such
a Lactobacillus strain will express and secretes the immuno-
genic protein in the intestinal region. DCs will be able to
capture such immunogen via the motifs of DC-binding
peptides. Such binding of an immunogen to DCs will
facilitate rapid internalization of the immunogen into
DCs. DCs will then process and present it to T cells resid-
ing in the gut. These cells will be activated and will circu-
late through the body in order to elicit specific T cell
immune responses against the pathogen of interest.
A transdermal delivery system also offers an interesting
route to approach DC subsets in order to enhance immu-
nity against cancer or pathogens. Accordingly, the
immune system of the skin harbors two very potent anti-
gen-presenting DC subsets which induce primary antigen
specific T cell immune responses [70]. Furthermore, care-
ful experimentation of various vaccine delivery routes has
shed light on the skin and its immune mechanisms. It has
previously been shown that cutaneous DC subsets can be
Transdermal delivery of immunogenic fusion protein by cutaneous DCs Figure 5
Transdermal delivery of immunogenic fusion protein by cutaneous DCs. Genetically engineered immunogenic fusion 
protein can be transdermaly administrated into the skin whereby cutaneous DC subsets can capture it via DC-peptide motifs 
fused to immunogen subunits. Loaded cutaneous DC subsets can be activated, leave the skin and enter the lymph nodes where 
they can present processed antigen as immunogenic peptides to T cells eliciting specific T cell immune responses.
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targeted and activated in situ in order to achieve specific T
cell mediated immune responses [70-74]. Thus, the feasi-
bility of using immunogenic DC-peptide fusion proteins
should be tested to determine whether administration of
such immunogenic fusion proteins will induce the activa-
tion of cutaneous DC subsets that in turn prime antigen-
specific T cells in situ.
DCs play a crucial role in host-pathogen interactions. A
recent example [75] involves the report in human papil-
loma virus 16 which is strongly associated with the devel-
opment of cervical cancer, that in infected cells the E6
oncogenic protein limits the numbers of LC in infected
epidermis. This appears to decrease the host's ability to
mount an effective immunological response to HPV 16.
We anticipate that future studies will be focused on
enhancing functional aspects of DCs to prevent such
events and establish novel vaccine strategies to efficiently
target immunogenic antigens or inhibitory agents to DCs
in order to elicit or suppress specific immune responses in
vivo.
Conclusions
1. Dendritic cells play a significant role in
immunopathogenesis.
2. The functions of dendritic cells involve cancer, infec-
tious diseases and tolerance.
3. Novel approaches in vaccine design can occur by target-
ing dendritic cells.
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